Business Wire·Jul 20, 2026, 6:59 AM ET

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

Bristol Myers Squibb (BMS) will expand its compute infrastructure by deploying NVIDIA DGX SuperPOD systems featuring DGX Vera Rubin NVL72 architecture.
This deployment establishes the most powerful & energy-efficient single-owned NVIDIA infrastructure in the life sciences sector for BMS.
The Vera Rubin architecture delivers up to ten times greater performance per megawatt compared to previous systems, enabling larger AI workloads without proportional energy increases.
The investment builds on nearly three years of collaboration & supports AI-driven programs across oncology, hematology, cardiovascular, immunology, & neuroscience.
Early AI results include agents that automate target identification to save scientists weeks of manual work & a "Predict First" approach where AI informs experimental design for small & large molecule programs.
The expanded infrastructure supports BMS's "hybrid intelligence" vision, where AI co-scientists handle data-intensive tasks while human researchers focus on direction, interpretation, & complex decision-making.
The Vera Rubin cluster will serve as the backbone for next-generation foundation models trained on BMS's proprietary data & will utilize NVIDIA's BioNeMo platform for biological AI.
BMS executives state the goal is to raise the probability of advancing the correct medicines by making better decisions faster through improved evidence & learning from every experiment.